SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Disease control and reduced glucocorticoid doses ...

Credit: Shutterstock. Crinecerfort is an investigational, oral, selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist. A phase 3 study evaluating the efficacy and safety of ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON -- Investigational crinecerfont reduced the need for ...

CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach FDA approval supported by data ...

Please provide your email address to receive an email when new articles are posted on . Crinecerfont, an oral nonsteroidal treatment, reduced mean daily glucocorticoid dose vs. placebo for people with ...

Crenessity is expected to be available commercially in approximately 1 week through PANTHERx Rare, a specialty pharmacy. The Food and Drug Administration (FDA) has approved Crenessity TM (crinecerfont ...

New CAHtalyst™ Pediatric and CAHtalyst™ Adult Phase 3 Clinical Study Data in Congenital Adrenal Hyperplasia CAHtalog™ Registry Data Highlighting Impact of Supraphysiologic Glucocorticoid Dosing Phase ...

BOSTON — Crinecerfont, an investigational oral selective corticotropin-releasing factor type 1 receptor antagonist, benefits both adults and children with congenital adrenal hyperplasia (CAH) due to ...

CAHmelia-203 Topline Results Anticipated in the First Quarter of 2024 CAHmelia-204 Completion of Enrollment Anticipated in Early First Quarter of 2024 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- ...